tumor lysis syndrome

1:52
MRD negativity as a treatment endpoint in CLL
Arnon Kater
2:43
MURANO update: MRD, biological subsets & safety analysis
John Seymour
2:06
MURANO study: exciting times in CLL
George Follows
3:36
Retrospective multicenter analysis of venetoclax-treated CLL patients
Anthony Mato
4:01
Primary analysis of MURANO study data for R/R CLL
John Seymour
8:06
Combination Treatment with Two Targeted Agents Shows Promise in Previously Treated CLL
Peter Hillmen
1:00
Managing and predicting TLS in CLL patients
Peter Hillmen
3:09
BCL2 inhibition and CLL: the role of venetoclax
Peter Hillmen
5:52
The power of venetoclax
Claire Dearden
1:16
Preliminary results of ibruntinib in combination with FCR chemotherapy for CLL
Matthew Davids
0:45
The importance of considering a CLL patient’s tumor lysis risk status
Matthew Davids
1:06
Safety analysis of the BCL-2 inhibitor venetoclax for CLL
Matthew Davids
1:34
Why venetoclax is a promising new drug for CLL
Paolo Ghia
The content of VJHemOnc is intended for healthcare professionals